Ensor Joe E
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Oncologist. 2014 Aug;19(8):886-91. doi: 10.1634/theoncologist.2014-0061. Epub 2014 Jul 7.
Biomarker validation, like any other confirmatory process based on statistical methodology, must discern associations that occur by chance from those reflecting true biological relationships. Validity of a biomarker is established by authenticating its correlation with clinical outcome. Validated biomarkers can lead to targeted therapy, improve clinical diagnosis, and serve as useful prognostic and predictive factors of clinical outcome. Statistical concerns such as confounding and multiplicity are common in biomarker validation studies. This article discusses four major areas of concern in the biomarker validation process and some of the proposed solutions. Because present-day statistical packages enable the researcher to address these common concerns, the purpose of this discussion is to raise awareness of these statistical issues in the hope of improving the reproducibility of validation study findings.
生物标志物验证与任何基于统计方法的其他验证过程一样,必须区分偶然发生的关联与反映真实生物学关系的关联。生物标志物的有效性通过验证其与临床结局的相关性来确立。经过验证的生物标志物可带来靶向治疗、改善临床诊断,并作为临床结局有用的预后和预测因素。诸如混杂和多重性等统计问题在生物标志物验证研究中很常见。本文讨论了生物标志物验证过程中四个主要关注领域以及一些提出的解决方案。由于当今的统计软件包使研究人员能够解决这些常见问题,因此本次讨论的目的是提高对这些统计问题的认识,以期提高验证研究结果的可重复性。